iPSC-derived Thymic Organoids
Immune Reconstitution / Oncology (e.g., Melanoma)
Pre-clinicalActive
Key Facts
Indication
Immune Reconstitution / Oncology (e.g., Melanoma)
Phase
Pre-clinical
Status
Active
Company
About Tolerance Bio
Tolerance Bio is developing thymus-based therapies to treat immune-mediated diseases by leveraging the organ's central role in establishing immune tolerance. The company has a seasoned leadership team with a proven track record in drug development and company building, including the founder who was instrumental in bringing teplizumab (TZIELD) to market. Backed by a $20.2 million seed round, Tolerance Bio is advancing a preclinical pipeline focused on implanted thymic organoids and has initiated a strategic R&D collaboration with ZipCode Bio. Its ambitious goal is to increase healthspan by fundamentally resetting immune function.
View full company profile